Cardiac Amyloidosis Follow-Up: What Is Monitored and When to Contact Your Team Early

The appointment letter said forty minutes. It took two hours, and the man in the corridor afterwards was holding three sheets of paper: a blood form, an echo request and a handwritten list of dates that stretched most of a year. He had come in expecting one diagnosis to end the uncertainty. He left with a schedule instead.

That is the honest shape of cardiac amyloidosis follow up. The condition, in which misfolded proteins settle into the heart muscle and stiffen it, is not managed in one decisive step. It is watched, measured and re-measured, because the numbers move slowly and the symptoms can lag behind them by months. Knowing what each test is for turns that stack of paper from a burden into a map.

This article walks through what is actually monitored, how often, why the two main types are followed differently, and, above all, which changes are worth a phone call before the next scheduled visit.

Why cardiac amyloidosis follow up looks different from ordinary heart failure care

Amyloidosis is a condition in which a normally soluble protein folds the wrong way, clumps into rigid fibers and lodges in tissues where it does not belong. When the target is the heart, the muscle walls thicken and stiffen. The pump may still squeeze reasonably well; the problem is that it cannot relax and fill. Cardiologists call this a restrictive pattern, and it behaves very differently from the weak, enlarged heart most people picture when they hear “heart failure”.

That distinction drives almost everything about the follow-up plan. Many standard heart-failure medicine classes, such as beta blockers and ACE inhibitors, work by slowing the heart or lowering blood pressure. A stiff heart that depends on a brisk rate and a decent filling pressure often tolerates them poorly, so clinicians tend to lean on careful fluid management instead, according to the Cleveland Clinic. Follow-up visits therefore spend as much time on blood pressure when standing, weight trends and kidney function as on the heart itself.

The second difference is that amyloid rarely stays in one organ. Two main types reach the heart. AL amyloidosis arises from abnormal plasma cells in the bone marrow producing fragments called light chains, and it is treated by a hematologist alongside the cardiologist. ATTR amyloidosis comes from transthyretin, a transport protein made in the liver; it can be inherited (a gene variant) or acquired with age, sometimes called wild-type. ATTR frequently also affects nerves, tendons and the spine.

So a follow-up visit is really a multi-organ audit. The heart is the headline, but the questions about tingling hands, dizziness on standing or changes in bowel habit are not small talk. They are data.

What test confirms cardiac amyloidosis, and why the type changes the plan

People often arrive at follow-up still unsure exactly how the diagnosis was made, so it helps to revisit it. Suspicion usually starts with an echocardiogram (an ultrasound of the heart) showing unusually thick walls, sometimes paired with an ECG that shows surprisingly small electrical signals for such a thick muscle. Neither proves amyloid on its own.

Confirmation rests on two branches. The first is a set of blood and urine tests looking for abnormal light chains. If those are clearly absent, a nuclear medicine scan using a bone-seeking tracer (often abbreviated PYP or DPD) can confirm ATTR cardiac amyloidosis without a biopsy, because the tracer clings to transthyretin deposits in the heart. This non-invasive route is now standard in most centers, as the Johns Hopkins Medicine overview describes.

If light chains are present, the picture is different. A scan cannot reliably distinguish AL from ATTR in that setting, so a tissue sample is needed, taken from fat under the skin, bone marrow or occasionally the heart itself, and typed under the microscope. Genetic testing follows a confirmed ATTR diagnosis to establish whether it is hereditary, which matters for relatives as much as for the patient.

Why does this matter at follow-up? Because the type sets the tempo. AL is a blood disorder first; its monitoring includes light-chain levels and hematology reviews on a schedule tied to treatment cycles. ATTR is slower and its monitoring leans toward heart imaging, nerve assessment and, in hereditary cases, family screening. If you are unsure which type you have, or whether genetic testing was done, that is a fair and useful question to ask at your next visit.

Which cardiac amyloidosis blood tests are repeated, and what each one tells the team

Blood tests do the heavy lifting between scans because they move earlier and cost the patient less effort than an echocardiogram. Four groups matter most.

NT-proBNP is a hormone fragment released when heart muscle is stretched under pressure. In amyloid hearts it tends to run high, and the trend over time is more informative than any single value. A sustained rise, rather than a one-off bump after a salty weekend, is one of the signals clinicians weigh when judging whether the disease is advancing.

Troponin is a protein that leaks from injured heart cells. Most people know it from heart-attack testing, where it spikes sharply. In amyloidosis it typically sits at a low, persistent level, a sign of ongoing low-grade damage. Together with NT-proBNP, it forms the basis of the staging systems used for both AL and ATTR cardiac disease.

Kidney function, usually reported as eGFR (an estimate of how much blood the kidneys filter per minute), is checked because amyloid can deposit in the kidneys, because diuretics stress them, and because a falling eGFR is itself part of staging in ATTR. A urine protein test often accompanies it, particularly in AL, where the kidney is the most common non-cardiac organ involved, as the NHS notes.

Free light chains apply to AL only. The difference between the abnormal and normal light chain, often written dFLC, is the hematologist’s main measure of whether treatment is controlling the underlying plasma-cell problem. It can respond within weeks, long before the heart shows any change on imaging.

Liver tests, thyroid function and a full blood count round out the panel, partly to track amyloid in other organs and partly to watch for treatment side effects.

How often is the heart scanned during cardiac amyloidosis monitoring?

Imaging answers questions blood tests cannot: how thick the walls are, how well the heart relaxes, and how much the muscle is straining to move blood.

The echocardiogram is the workhorse. Beyond wall thickness, modern echo measures something called strain, a percentage describing how much each segment of muscle shortens with every beat. Amyloid produces a distinctive pattern in which the base of the heart moves poorly while the tip is relatively spared; sonographers sometimes describe the resulting map as a “cherry on top”. Changes in strain can appear before the ejection fraction (the proportion of blood pumped out each beat) falls, which is why teams track it. Repeat echoes for stable patients commonly happen roughly once a year, with earlier scans if symptoms or blood tests shift, according to the Cleveland Clinic.

The ECG is quick and repeated at most visits. Its jobs are to catch conduction problems, where the heart’s electrical signal slows or blocks on its way from the upper to the lower chambers, and to spot atrial fibrillation, an irregular rhythm common in amyloid hearts. A portable monitor worn for a day or longer may be added if palpitations or unexplained dizziness are reported.

Cardiac MRI gives detailed pictures of the muscle and can quantify the amount of expanded tissue between cells, a proxy for amyloid load. It is powerful but slow and not always repeated routinely; many teams reserve it for unclear cases or research protocols. The nuclear bone-tracer scan that confirmed the diagnosis is rarely repeated, because a positive scan tends to stay positive regardless of how the patient is doing.

A six-minute walk test, which measures how far a person can walk on a flat corridor in six minutes, is sometimes bundled in. It is unglamorous, but it captures real-world capacity in a way a scan cannot.

Who is followed closely, and who is usually asked to wait and watch?

Not everyone who hears the word amyloid needs the same intensity of follow-up, and being placed in a lighter pathway is not neglect. It reflects where the evidence says risk lies.

Closest attention goes to people with AL amyloidosis and heart involvement. Because light chains are directly toxic to heart cells, the condition can change over weeks, and treatment decisions hinge on the light-chain response and on markers such as NT-proBNP and troponin. Visits are tied to treatment cycles and are frequent during active therapy, according to Mayo Clinic.

People with symptomatic ATTR cardiac disease, whether hereditary or wild-type, sit in the middle. Their disease usually advances over years rather than months, and structured reviews at intervals of several months to a year are the common pattern, tightened if function slips.

Then there are people who carry a transthyretin gene variant but have no evidence of disease. Some variants cause symptoms in the thirties; others rarely do before the seventies, and some carriers never develop disease at all. Guideline groups generally suggest carriers begin periodic screening a decade or so before the age at which their variant typically causes symptoms, with a baseline set of tests and repeats at agreed intervals. This is genuinely a watch-and-wait position, and it is not the same as doing nothing.

A further group has amyloid spotted by chance: a scan for something else, or a tendon or spinal specimen sent to the lab that happens to stain positive. If heart tests are normal, these people are often reviewed yearly rather than treated, because current disease-modifying therapies are studied and approved in people with established cardiac involvement, not in those without it.

Whichever group you fall into, the decision about pathway rests with your treating team, and it can change as new information arrives.

A typical cardiac amyloidosis follow-up schedule at a glance

Every center writes its own protocol, and individual plans vary with age, kidney function and treatment. The table below shows the common ingredients and the intervals that guideline and consensus documents tend to describe for someone who is clinically stable. It is a summary to help you read your own schedule, not a standard to hold your team to.

What is checked	Why it matters	Typical interval when stable
Symptoms, weight, standing and lying blood pressure	Fluid status and autonomic nerve involvement	Every visit; weight daily at home
NT-proBNP and troponin	Heart strain and ongoing muscle injury; staging	Roughly every 3 to 6 months in ATTR; each cycle in AL
Kidney function, urine protein	Amyloid in kidneys; diuretic effects	With each blood draw
Free light chains (AL only)	Whether the plasma-cell disorder is controlled	Each treatment cycle, then every few months
ECG	Conduction block, atrial fibrillation	Every visit
Echocardiogram with strain	Wall thickness, filling, muscle function	About yearly, sooner if change suspected
Six-minute walk or functional class	Real-world capacity	Every 6 to 12 months
Neurology and other-organ review	Nerves, gut, carpal tunnel, eyes in hereditary ATTR	Yearly or as symptoms suggest

Two patterns are worth noticing. First, cheap and quick tests are repeated often, while expensive or slow ones are spaced out and pulled forward only when the cheap ones move. Second, the schedule is built around the type. An AL patient in active treatment may be seen more often in three months than an ATTR patient is in two years. Neither is being over- or under-treated; they simply have different diseases sharing a name.

If your own plan looks lighter or heavier than this, ask why. There is almost always a reason, and hearing it makes the appointments easier to keep.

How quickly does cardiac amyloidosis progress?

This is the question most people are really asking when they ask about follow-up, and the truthful answer is that the two types run on different clocks and individuals vary widely within each.

AL cardiac amyloidosis is the faster of the two. Light chains injure heart cells directly, not only by piling up as deposits, so people can decline over months if the plasma-cell disorder is not brought under control. That urgency is why hematology treatment tends to start promptly after diagnosis and why the early follow-up is dense. When treatment does suppress the light chains, heart markers such as NT-proBNP may stabilize or improve over subsequent months, although the deposits themselves clear slowly, if at all, according to Mayo Clinic.

ATTR is generally slower. Wild-type disease is often diagnosed in the seventies or eighties after years of quiet accumulation, and progression is typically measured in years. Hereditary forms vary by variant; some behave like wild-type, others involve nerves early and move faster. Because the pace is gentler, the signal of change is subtler and the tests are spaced further apart.

What does “progression” actually mean to the team? It is rarely one number. Clinicians look for a pattern: a sustained rise in NT-proBNP beyond normal day-to-day variation, a fall in kidney function, a shorter six-minute walk distance, a step down in functional class (the everyday-activity grading used in heart failure), new conduction problems on ECG or a worsening strain pattern on echo. Any one of these alone can be noise; several together are a trend.

Two honest caveats. Symptoms lag behind markers, so feeling the same does not guarantee stability. And a single bad set of results after an infection or a spell of dehydration does not mean the disease has jumped forward. The team’s job is to separate signal from noise, and that is precisely why the tests are repeated rather than done once.

What the first weeks and months after starting treatment usually look like

People often expect to feel a treatment working. With amyloidosis that expectation needs resetting, because the goal of most current therapies is to slow or stop the disease rather than to reverse damage already done.

For ATTR, two classes of disease-modifying medicine exist. Stabilizers bind the transthyretin protein so it is less likely to fall apart and misfold; gene silencers reduce the liver’s production of the protein in the first place. Both act upstream of the heart. Their effect is judged over many months by whether markers and function hold steady compared with the expected decline, not by a rapid change in how someone feels. Blood levels of transthyretin can fall within weeks of starting a silencer, which teams may check as a sign the medicine is doing its job, but that is a laboratory marker, not a symptom. Whether, when and which to start is entirely a decision for the prescribing clinician, who weighs kidney function, disease stage and other conditions.

For AL, treatment is directed at the plasma cells and is usually a combination regimen similar to those used for related blood cancers. The hematologist tracks the light-chain response after each cycle, and the depth of that response is the main early readout. Heart markers are checked alongside because the cardiac response typically follows, sometimes by months.

In the early weeks after any new therapy, follow-up also watches for side effects: kidney or liver tests, blood counts, infusion reactions, nerve symptoms. Fluid management often needs re-tuning in the same period because appetite, weight and activity shift.

The pattern many people describe is that nothing dramatic happens, then a scan or blood test a year later shows the line has flattened. In this condition, boring is often the aim.

Symptoms of worsening cardiac amyloidosis: how your team reads change between visits

Because the disease moves quietly, clinicians rely heavily on a handful of home observations to catch drift between appointments. Understanding what they are looking for helps you report the right things rather than everything.

Weight is the first. In a stiff heart the earliest sign of fluid building up is often not swollen ankles but a creeping number on the scale. Teams typically ask for a morning weight, after using the bathroom and before eating, on the same scale each day. It is the trend over several days that matters. The American Heart Association describes a gain of two to three pounds in a day or five pounds in a week as a reason for heart-failure patients to contact their care team, and many amyloid clinics use similar thresholds or set a personal one.

Blood pressure taken lying and then standing is the second. Amyloid can damage the autonomic nerves that tighten blood vessels when you stand, so pressure drops and lightheadedness follows. The condition is called orthostatic hypotension. A widening gap between lying and standing readings tells the team that nerve involvement may be advancing or that diuretic doses need review, and it changes how aggressively fluid can be removed.

Effort tolerance is the third. Rather than a checklist, teams want a comparison: the flight of stairs you managed last month, the distance to the shop, whether you now stop halfway. Waking breathless at night or needing extra pillows are classic signals worth mentioning, as are new palpitations or a pulse that feels irregular, since atrial fibrillation is common and raises stroke risk.

Finally, the less obvious changes: reduced appetite or early fullness, altered bowel habit, numbness or tingling in the feet, or unexpected bruising around the eyes in AL. None of these diagnoses anything on its own. Together they give the clinician the texture that a blood test cannot.

Medicines under review at every visit: fluid tablets, rhythm drugs and what is usually avoided

Much of a follow-up conversation is about medicines that are not the headline therapy, because they are the ones that change most often.

Loop diuretics, water tablets that make the kidneys excrete more salt and water, are the backbone of symptom control. The balance is delicate: too little and fluid backs up into the lungs and legs; too much and blood pressure falls, kidneys strain and dizziness on standing worsens. Teams adjust them against weight, kidney tests and standing blood pressure, and sometimes ask patients to follow an agreed plan for small changes at home. That plan belongs to the prescriber; changing or stopping a diuretic because the swelling has gone is a common route to a hospital admission, as the Cleveland Clinic warns.

Several drug classes routinely used in other kinds of heart failure are approached cautiously here. Beta blockers slow the heart rate; a stiff heart that cannot enlarge its stroke volume relies on rate to maintain output, so slowing it can cause fatigue and low blood pressure. Calcium channel blockers and cardiac glycosides can bind to amyloid fibers, which is thought to increase their effects unpredictably. None of these is absolutely forbidden, and some patients take them for other reasons under supervision, but their presence on a medication list is something the team reviews at each visit.

Atrial fibrillation is frequent, and because the stiff, poorly contracting upper chambers encourage clots, most guidelines favor anticoagulation (blood-thinning medicine) once the rhythm appears, often regardless of the usual risk scores. Bleeding risk, kidney function and falls are weighed on the other side, and that judgment is remade over time.

Conduction problems may eventually call for a pacemaker, a small device that keeps the heart rate from dropping. The ECG at each visit is partly a check on whether that conversation is approaching.

Beyond the heart: nerves, kidneys, hands and eyes in long-term follow-up

The heart may have brought you to the clinic, but the follow-up plan is deliberately wider, and some of the most useful early warnings come from elsewhere.

Nerve involvement is the big one in ATTR, especially hereditary forms. Deposits in peripheral nerves cause numbness, tingling or burning that usually begins in the feet and climbs. Deposits in autonomic nerves cause the standing blood-pressure drops discussed above, along with constipation alternating with diarrhea, early satiety, bladder problems and sexual dysfunction. A neurologist may be part of the team, and simple bedside tests of sensation and a standardized questionnaire are often repeated yearly to track change, as the NHS overview describes.

Musculoskeletal clues are surprisingly common. Carpal tunnel syndrome on both sides, a ruptured biceps tendon or narrowing of the spinal canal in the lower back can precede heart symptoms by years in wild-type ATTR. Once the diagnosis is made, these are asked about not because they are dangerous but because they help the team understand the tempo of your disease.

Kidneys are the priority in AL, where protein leaking into the urine is a sign of deposits in the filtering units. Kidney function and urine protein are followed alongside light chains, and worsening in either may prompt the hematologist to reassess treatment. Liver enlargement and, less often, gut or skin involvement are also monitored in AL.

Eyes matter in some hereditary ATTR variants, where deposits can cloud the vitreous gel or raise pressure inside the eye. A yearly eye check is often built into the plan for those variants specifically.

The practical point is that a symptom in an unexpected place is still relevant. Telling the cardiologist about your bowels can feel odd; in this condition it is exactly the kind of joined-up thinking follow-up is designed to capture.

What people often get wrong about cardiac amyloidosis follow-up

Some beliefs surface again and again in clinic, and correcting them changes how people use their appointments.

“I feel fine, so the disease must be stable.” Symptoms are a late indicator. Markers and imaging can drift for months before breathlessness changes, which is exactly why blood tests are repeated even when nothing feels different.

“The scan that diagnosed me will show whether I’m getting better.” The nuclear bone-tracer scan is excellent at saying yes or no to ATTR, but it is not a reliable gauge of how much amyloid is there or whether it has changed. Teams track strain, blood markers and function instead.

“The new medicine will dissolve the deposits.” Current stabilizers and silencers are designed to slow further build-up. Evidence that they remove existing amyloid from the heart is limited and under study, so the realistic aim is a flatter line rather than a return to a previous baseline, as Johns Hopkins Medicine explains.

“Once the swelling is gone I can stop the water tablets.” The swelling is gone because of them. Any change to a diuretic plan should come from the prescriber, ideally with an agreed protocol so you know what to do when weight moves.

“Amyloidosis is always rapid and always fatal.” That reflects the history of AL before modern therapies and does not describe the slow course typical of wild-type ATTR, nor the outcomes now seen in AL when light chains are controlled early. Prognosis is individual, staged by markers, and best discussed with your own team rather than inferred from older statistics.

“Only older men get it.” Wild-type ATTR is indeed more common in older men, but AL affects women and men across middle age and beyond, and hereditary ATTR can appear in the thirties. Follow-up plans are built around the type and stage, not the stereotype.

Questions to ask your care team at your next cardiac amyloidosis visit

A follow-up appointment goes better when you arrive with three or four specific questions rather than a general sense of worry. These are the ones clinicians say they wish patients asked more often.

• Which type of amyloidosis do I have, and has genetic testing been done or considered? If a variant was found, should my relatives be offered screening, and from what age?
• Which two or three numbers are you watching most closely in my case, and roughly what change in them would prompt you to act? Knowing whether it is NT-proBNP, kidney function or walk distance makes results letters far less alarming.
• What is my personal weight threshold for calling, and is there an agreed plan for adjusting my fluid tablets at home?
• Should I be checking my blood pressure lying and standing, and what gap between the two would you want to hear about?
• Are any of my current medicines, including ones prescribed elsewhere, on the list that is used cautiously in amyloid hearts?
• How will we know whether my disease-modifying treatment is doing its job, and over what timescale should I expect to see that judgment made?
• Do I have any signs of nerve, kidney or other-organ involvement, and who is following those?
• If my rhythm becomes irregular, what is the plan, and have we discussed blood thinning?
• Is there a clinical trial I might be eligible for, and would joining one change my routine follow-up?
• Who do I contact between visits, what hours are they available, and what should I do outside those hours?

Bring your home weight and blood-pressure log, a current medication list including supplements, and a note of anything new since the last visit, even if it seems unrelated to the heart. Writing down the answers, or bringing someone who will, is not a sign of anxiety. It is how a complicated plan gets followed.

When to call your doctor: red-flag signs that should not wait for the next appointment

Scheduled follow-up catches slow drift. It cannot catch a sudden turn, and in cardiac amyloidosis certain changes deserve a same-day call to your team or, in some cases, emergency services. This paragraph is the one to remember: seek urgent help if you faint or nearly faint, develop new chest pain or pressure, become breathless at rest or wake gasping, notice a rapid or newly irregular heartbeat with dizziness, or have signs of a stroke such as facial drooping, arm weakness or slurred speech. Those situations warrant calling 911 or your local emergency number rather than waiting for a callback.

Contact your team the same day, without waiting for the scheduled visit, for a weight gain of two to three pounds overnight or five pounds across a week, the thresholds the American Heart Association uses for heart-failure self-monitoring; for swelling that climbs from the ankles toward the knees or reaches the abdomen; for a marked drop in how far you can walk over a few days; for a standing blood pressure well below your usual with lightheadedness; for passing much less urine than normal; or for persistent vomiting or diarrhea that stops you keeping fluids and medicines down. Each of these can tip fluid balance quickly in a stiff heart.

People on AL treatment should also report fever or shaking chills promptly, because the medicines can lower resistance to infection, and new unexplained bruising or bleeding. Anyone on blood thinners should report black stools, blood in urine or a fall with a head knock.

Calf pain and swelling on one side, or sudden sharp breathlessness with chest pain, can indicate a clot and should be treated as an emergency.

Clinics would rather hear from you and reassure you than learn a week later that you sat on a change. Every decision about what happens next belongs to the treating team, but the timing of the call belongs to you, and earlier is almost always better.

Frequently asked questions

What is the 5 5 5 rule for amyloidosis?

There is no “5 5 5 rule” in the major cardiology or hematology guidelines for amyloidosis, and the phrase appears to be an internet shorthand rather than a clinical standard. Staging in both AL and ATTR is based on measured blood markers such as NT-proBNP, troponin, kidney function and, in AL, the difference between free light chains. If you have seen a rule quoted somewhere, ask your team what it referred to.

How fast does cardiac amyloidosis progress?

It depends mainly on the type. AL cardiac amyloidosis can worsen over months if the light chains are not controlled, because they injure heart cells directly. ATTR, especially the wild-type form, usually advances over years. Within each type, individuals vary widely, and progression is judged by trends in blood markers, echo strain and walking capacity rather than by a single result or by symptoms alone.

What test confirms cardiac amyloidosis?

For ATTR, a nuclear bone-tracer scan combined with blood and urine tests showing no abnormal light chains can confirm the diagnosis without a biopsy. For AL, or when light chains are present, a tissue sample from fat, bone marrow or occasionally the heart is examined and typed. Genetic testing follows a confirmed ATTR diagnosis to establish whether it is hereditary.

What are the symptoms of worsening cardiac amyloidosis that my team watches for?

Clinicians look for a pattern rather than one sign: a rising trend in home weight, swelling moving up the legs, breathlessness on less exertion or when lying flat, lightheadedness on standing, new palpitations or an irregular pulse, and reduced urine output. New numbness in the feet or digestive changes can point to nerve involvement. Report these promptly; interpreting them is the team’s job, not yours.

Which cardiac amyloidosis blood tests are repeated most often?

NT-proBNP, troponin and kidney function are the core repeat tests in both types because they underpin staging and respond earlier than imaging. In AL, free light chains are added and tracked with each treatment cycle. Liver tests, thyroid function and a full blood count are checked periodically for other-organ involvement and treatment side effects.

How often should I have an echocardiogram for cardiac amyloidosis monitoring?

For someone who is clinically stable, repeat echocardiograms are commonly done about once a year, with an earlier scan if symptoms change or blood markers shift. The echo tracks wall thickness, filling and strain, a measure of how much each segment of muscle shortens. Your own interval may differ, and the treating team sets it based on type, stage and treatment.

Why are some heart failure medicines avoided in cardiac amyloidosis?

Because the amyloid heart is stiff rather than weak, it depends on heart rate and adequate filling pressure to maintain output. Beta blockers slow the rate and some blood-pressure drugs lower filling pressure, so they can cause fatigue and dizziness. Certain calcium channel blockers and cardiac glycosides can bind to amyloid fibers, making their effects unpredictable. None is absolutely forbidden; each is a judgment for the prescriber.

Do stabilizer or silencer medicines remove amyloid from the heart?

Current evidence shows these medicines slow further transthyretin deposition by stabilizing the protein or reducing its production. Evidence that they clear existing deposits from the heart is limited and still being studied. The realistic goal of follow-up is to see markers and function hold steadier than would be expected without treatment, judged over many months by the prescribing clinician.

If I carry a transthyretin gene variant but have no symptoms, do I need follow-up?

Yes, but usually a lighter, screening-style plan. Guideline groups generally suggest carriers begin periodic checks about a decade before the age their specific variant typically causes symptoms, with a baseline assessment and repeat tests at agreed intervals. Treatment is normally reserved for people with established disease, so this is genuine watch-and-wait rather than neglect.

What should I bring to a cardiac amyloidosis follow-up appointment?

Bring your daily weight log, any home blood-pressure readings taken lying and standing, a complete medication list including supplements and drugs prescribed elsewhere, and a short note of anything new since the last visit, however unrelated it seems. A written list of questions and, if possible, someone to help remember the answers makes a complex plan much easier to follow.

References

• MedlinePlus Medical Encyclopedia: Cardiac amyloidosis
• NHS: Amyloidosis

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.